Cannovex is a Belgian-based biotechnology company developing first-in-class cannabis-based medicines.
Starting from a unique and proprietary collection of diversified and rare cannabis genetics, we breed and register highly specific medicinal plants. We go beyond the world’s highest cultivation standards to ensure an ultra-stabilized pattern of plant components. These components are carefully selected to target specific diseases.
Our plant materials serve as a leading-edge API-platform which we develop further into patented prescription medications for many different indications and in diverse pharmaceutical forms and dosages.
In collaboration with EU University Hospitals we bring our products to EMA regulated clinical trials for various diseases, leading to proof-of-concepts (PoC).
These Cannovex PoC are the basis for partnerships with pharmaceutical companies to run end-stage clinical trials and to commercialize our products on a global scale.